Immunogenic Composition for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapeutic treatments for breast cancer are hindered by inadequate preparative methods, resulting in compounds with insufficient immunoactivity, leading to high rates of relapse and metastasis.
Innovation Solution
An immunogenic composition comprising an immunoactive tissue extract, a BCG solution as an immune response activator, and a formaldehyde solution as an immune response mitigator, specifically formulated to stimulate an immune response against cancer cells, is developed. This composition includes a protein concentration of 6-10 mg/kg, 0.525-0.725 mg/mL of BCG, and 0.005-0.035% formaldehyde, and is administered intradermally to cancer subjects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapeutic treatments are used, then cancer treatment is provided, but immunoactivity is insufficient leading to high relapse rates
Solution Approach 1:
The patent applies parameter changes by optimizing the concentration of protein composition (6-10 mg/kg), adjusting BCG solution concentration (0.525-0.725 mg/mL), and controlling formaldehyde concentration (0.005-0.035%) to achieve the desired immunoactivity and reduce relapse rates
Solution Approach 2:
The patent creates a composite immunogenic composition by combining multiple components: immunoactive tissue extract, BCG solution as immune response activator, and formaldehyde solution as immune response mitigator, where each component synergistically enhances the overall immunotherapeutic effect
2Reliability
If adequate immunoactivity is achieved through improved preparative methods, then relapse rates are reduced, but treatment complexity increases
Solution Approach 1:
The patent segments the immunogenic composition into distinct functional components: immunoactive tissue extract (antigen source), BCG solution (immune activator), and formaldehyde solution (response mitigator), allowing each component to be optimized independently while maintaining overall therapeutic efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunogenic composition effectively triggers an immune response, reducing tumor growth and relapse rates, as demonstrated by significant necrosis and immune cell infiltration in treated subjects, with improved survival rates and reduced side effects compared to conventional treatments.
Implementation Method 1
an immune response activator comprising a BCG solution (e.g., a live attenuated Danish strain 1331)
Implementation Method 2
an immune response mitigator comprising a formaldehyde solution
Implementation Method 3
an immunoactive tissue extract comprising a protein composition
Data Source
AI summary
The present disclosure relates, in some embodiments, to an immunogenic compositions for the treatment of cancer, methods of preparing an immunogenic composition for the treatment of cancer, and methods of treating cancer subjects with an immunogenic composition.Some embodiments of the present disclosure relate to an immunogenic composition operable as a treatment of cancer in a subject having a subject weight, the immunogenic composition including: an immunoactive tissue extract comprising a protein composition, wherein the immunogenic composition has a final concentration of the protein composition of about 6 mg to about 10 mg of the protein composition per kg of the subject weight; an immune response activator comprising a BCG solution, wherein the immunogenic composition has a final concentration of the immune response activator of about 0.525 to about 0.725 mg of the BCG solution per mL of the immunogenic composition; and an immune response mitigator comprising a formaldehyde solution, wherein the immunogenic composition has a final concentration of the formaldehyde solution of about 0.005% to about 0.035%.